NCT03568890Active, not recruitingPhase 4
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 510 (estimated)
- First submitted
- 14 Jun 2018
- Start date
- 1 Sept 2018
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT03568890
- EU CT number
- 2025-520954-12-00
- EudraCT number
- 2018-003621-28
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 510
- From 1 Sept 2018 to the primary completion date, 1 Aug 2025
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Absolute contraindications for anticoagulation therapy
- Absolute contraindications for antiplatelet therapy
- Recent percutaneous revascularization with drug-eluting stents requiring dual antiplatelet therapy
- Prior intracranial hemorrhage
- Major/life-threatening bleeding event within the month prior to LAAC
- Multiple bleeding events (minor or major) within the month prior to LAAC
Other illness
- End-stage renal disease (CrCl \<15 ml/min)
- Major/life-threatening bleeding within the first 24 hrs following LAAC
Other
- Contraindications for TEE
- Severe pericardial effusion within the first 24 hrs following LAAC
Who the study is looking for
- Successful transcatheter LAAC with any approved device
- Age≥18 years old
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Josep Rodes-Cabau Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| Hospital de la Santa Creu i Sant Pau Coordinator of this site? Confirm its status | Barcelona | Spain | Not yet recruiting |
| Hospital Clinic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Not yet recruiting |
| Bellvitge University Hospital Coordinator of this site? Confirm its status | L'hospitalet De Llobregat | Spain | Not yet recruiting |
| Hospital Clínico San Carlos Coordinator of this site? Confirm its status | Madrid | Spain | Not yet recruiting |
| Instituto Bernabeu Palma De Mallorca S.L. Coordinator of this site? Confirm its status | Palma | Spain | Not yet recruiting |
| Area De Salud De Salamanca Coordinator of this site? Confirm its status | Salamanca | Spain | Not yet recruiting |
| Hospital Alvaro Cunqueiro Coordinator of this site? Confirm its status | Vigo | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.